Targeted disruption of the murine lecithin:cholesterol acyltransferase gene is associated with reductions in plasma paraoxonase and platelet- activating factor acetylhydrolase activities but not in apolipoprotein J concentration

Journal of Lipid Research

Volumn 40, Issue 7, 1999, Pages 1276-1283

  Forte, Trudy M ^a   Oda, Michael N ^a   Knoff, Laura ^a   Frei, Balz ^b   Suh, Jung ^b   Harmony, Judith A K ^c   Stuart, William D ^c   Rubin, Edward M ^a   Ng, Dominic S ^a,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b OREGON STATE UNIVERSITY   (United States)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^d ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

Antioxidative enzymes; ApoA I; Fast protein liquid chromatography; LCAT deficiency; Lipid hydroperoxides; Nascent HDL

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ANTIOXIDANT; APOLIPOPROTEIN A1; ARYLDIALKYLPHOSPHATASE; CLUSTERIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID HYDROPEROXIDE; MESSENGER RNA; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; GENE DISRUPTION; HYPOLIPOPROTEINEMIA; LIPOPROTEIN BLOOD LEVEL; MOUSE; NONHUMAN; PRIORITY JOURNAL;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ANIMALS; APOLIPOPROTEIN A-I; ARYLDIALKYLPHOSPHATASE; CHOLESTEROL; CLUSTERIN; ESTERASES; GLYCOPROTEINS; LIPID PEROXIDATION; LIVER; MICE; MICE, INBRED C57BL; MICE, INBRED DBA; MICE, KNOCKOUT; MOLECULAR CHAPERONES; PHOSPHATIDYLCHOLINE-STEROL O-ACYLTRANSFERASE; PHOSPHOLIPASES A; PLATELET ACTIVATING FACTOR; RNA, MESSENGER;

EID: 0032807348     PISSN: 00222275     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Glomset, J. A., G. Assmann, E. Gjone, and K. R. Norum. 1995. Lecithin:cholesterol acyltransferase deficiency and fish-eye disease. In The Metabolic Basis of Inherited Diseases. C. R. Scriver, A. L. Beaudent, W. S. Sly, and D. Valle, editors. McGraw-Hill, New York, NY. 1933-1952.
2. Kuivenhoven, J. A., A. F. H. Stalenhoef, J. S. Hill, P. N. M. Demacker, A. Errami, J. J. P. Kastelein, and P. H. Pritchard. 1996. Two novel molecular defects in the LCAT gene are associated with fish eye disease. Arterioscler. Thromb. Vasc. Biol. 16: 294-303.
3. Forte, T., K. R. Norum, J. A. Glomset, and A. V. Nichols. 1971. Plasma lipoproteins in familial lecithin:cholesterol acyltransferase deficiency: structure of low and high density lipoproteins as revealed by electron microscopy. J. Clin. Invest. 50: 1141-1148.
4. Shih, D. M., S. Hama, L. Gu., Y-R. Xia, M. Navab, A. M. Fogelman, and A. J. Lusis. 1996. Genetic-dietary regulation of serum paraoxonase expression and its role in atherogenesis in a mouse model. J. Clin. Invest. 97: 1630-1639.
5. Uriel, J. 1961. Charactérisation des cholinestérases et d'autres estérases cardoxylique après électrophorèse et immunoélectrophorèse en gelose I. Applications à l'étude des estérases du serum humain normal. Ann. Inst. Pasteur. 101: 104-119.
6. La Du, B. N. 1992. Human serum paraoxonase/arylesterase. In Pharmacogenetics of Drug Metabolism. Pergamon Press, Inc., New York. 51-91.
7. Mackness, M. I., and P. N. Durrington. 1995. HDL, its enzymes and its potential to influence lipid peroxidation. Atherosclerosis. 115: 243-253.
8. Blatter, M. C., R. W. James, S. Messmer, F. Barja, and D. Pometta. 1993. Identification of a distinct human high-density lipoprotein subspecies defined by a lipoprotein-associated protein, K-45. Identity of K-45 with paraoxonase. Eur. J. Biochem. 211: 871-879.
9. Navab, M., S. Hama-Levy, B. J. Van Lenten, G. C. Fonarow, C. J. Cardines, L. W. Castellani, M. Brennan, A. J. Lusis, and A. M. Fogelman. 1997. Mildly oxidized LDL induces an increased apolipoprotein J/paraoxonase ratio. J. Clin. Invest. 99: 2005-2019.
10. Mackness, M. I. 1989. A-esterases: enzymes looking for a role? Biochem. Pharmacol. 38: 385-390.
11. Mackness, M. I., S. Arrol, C. Abbott, and P. N. Durrington. 1993. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis. 104: 129-135.
12. Watson, A. D., J. A. Berliner, S. Y. Hama, B. N. La Du, K. F. Faull, A. M. Fogelman, and M. Navab. 1995. Protective effect of high density lipoprotein-associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J. Clin. Invest. 96: 2882-2891.
13. Shih, D. M., L. Gu, Y-R. Xia, M. Navab, W-F. Li, S. Hama, L. W. Castellani, C. E. Furlong, L. G. Costa, A. M. Fogelman, and A. J. Lusis. 1998. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature. 394: 284-287.
14. Stafforini, D. M., M. R. Elstad, T. M. McIntyre, G. A. Zimmerman, and S. M. Prescott, 1990. Human macrophages secrete platelet-activating factor acetylhydrolase. J. Biol. Chem. 65: 9682-9687.
15. Tjoelker, L. W., C. Wilder, C. Eberhardt, D. M. Stafforini, G. Dietsch, B. Schimpf, S. Hooper, H. Le Trong, and L. S. Cousens. 1995. Anti-inflammatory properties of a platelet-activating factor acetylhydrolase. Nature. 374: 549-553.
16. Stremler, K. E., D. M. Stafforini, S. M. Prescott, G. A. Zimmerman, and T. M. McIntyre. 1989. An oxidized derivative of phosphatidylcholine is a substrate for the platelet-activating factor acetylhydrolase from human plasma. J. Biol. Chem. 264: 5331-5334.
17. Stremler, K. E., D. M. Stafforini, S. M. Prescott, and T. M. McIntyre. 1991. Human plasma platelet-activating factor acetylhydrolase: oxidatively-fragmented phospholipids as substrates. J. Biol. Chem. 266: 11095-11103.
18. Stafforini, D. M., M. E. Carter, G. A. Zimmerman, T. M. McIntyre, and S. M. Prescott. 1989. Lipoproteins alter the catalytic behavior of the platelet-activating factor acetylhydrolase in human plasma. Proc. Natl. Acad. Sci. USA. 86: 2393-2397.
19. Tselepis, A. D., C. Dentan, S. A. P. Karabina, M. J. Chapman, and E. Ninio. 1995. PAF-degrading acetylhydrolase is preferentially associated with dense LDL and VHDL-1 in human plasma. Arterioscler. Thromb. Vasc. Biol. 15: 1764-1773.
20. Stafforini, D. M., G. A. Zimmerman, T. M. McIntyre, and S. M. Prescott. 1992. The platelet-activating factor acetylhydrolase from human plasma prevents oxidative modification of low-density lipoprotein. Trans. Assoc. Am. Phys. 105: 44-63.
21. Watson, A. D., M. Navab, S. Y. Hama, A. Sevanian, S. M. Prescott, D. M. Stafforini, T. M. McIntyre, B. N. La Du, A. M. Fogelman, and J. A. Berliner. 1995. Effect of platelet activating factor-acetylhydrolase on the formation and action of minimally oxidized low density lipoprotein. J. Clin. Invest. 95: 774-782.
22. Tsaoussis, V., and C. Vakirtzi-Lemonias. 1994. The mouse plasma PAF acetylhydrolase: II. It consists of two enzymes both associated with the HDL. J. Lipid Mediat. Cell Signal. 9: 317-331.
23. Kelso, G., W. D. Stuart, R. J. Richter, C. E. Furlong, T. C. Jordan-Starck, and J. A. K. Harmony. 1994. Apolipoprotein J is associated with paraoxonase in human plasma. Biochemistry. 33: 832-839.
24. Jordan-Starck, T. C., D. P. Witte, B. J. Aronow, and J. A. K. Harmony. 1992. Apolipoprotein J: a membrane policeman? Curr. Opin. Lipidol. 3: 75-85.
25. de Silva, H. V., J. A. K. Harmony, W. D. Stuart, C. M. Gil, and J. Robbins. 1990. Apolipoprotein J: structure and tissue distribution. Biochemistry. 29: 5380-5389.
26. James, R. W., A. C. Hochstrasser, I. Borghini, B. Martin, and D. Hochstrasser. 1991. Characterization of a human high density lipoprotein-associated protein, NA1/NA2. Arterioscler. Thromb. 11: 645-652.
27. Aronow, B. J., S. D. Lund, T. L. Brown, J. A. K. Harmony, and D. P. Witte. 1993. Apoliprotein J expression at fluid-tissue interfaces: potential role in barrier cytoprotection. Proc. Natl. Acad. Sci. USA. 90: 725-729.
28. Gelissen, I., T. Hochbrebe, M. R. Wilson, S. B. Easterbrook-Smith, W. Jessup, R. T. Dean, and A. J. Brown. 1998. Apolipoprotein J (clusterin) induces cholesterol export from macrophage-foam cells: a potential anti-atherogenic function. J. Biochem. 331: 231-237.
29. Ng, D. S., O. L. Francone, T. M. Forte, J. Zhang, M. Haghpassand, and E. M. Rubin. 1997. Disruption of the murine lecithin:cholesterol acyltransferase gene causes impairment of adrenal lipid delivery and up-regulation of scavenger receptor class B type I. J. Biol. Chem. 272: 15777-15781.
30. Gan, K. N., A. Smolen, H. W. Eckerson, and B. N. La Du. 1991. Purification of human serum paraoxonase/arylesterase. Drug Metab. Disp. 19: 100-106.
31. Stafforini, D. M., S. M. Prescott, and T. M. McIntyre. 1987. Human plasma platelet-activating factor acetylhydrolase. J. Biol. Chem. 262: 4223-4230.
32. Rubin, E. M., B. Y. Ishida, S. M. Clift, and R. M. Krauss. 1991. Expression of human apolipoprotein A-I in transgenic mice results in reduced plasma levels of murine apolipoprotein A-I and the appearance of two new high density lipoprotein size subclasses. Proc. Natl. Acad. Sci. USA. 88: 434-438.
33. Frei, B., Y. Yamamoto, D. Niclas, and B. N. Ames. 1988. Evaluation of an isoluminol chemiluminescence assay for the detection of hydroperoxides in human blood plasma. Anal. Biochem. 175: 120-130.
34. Yamamoto, Y., B. Frei, and B. N. Ames. 1990. Assay of lipid hydroperoxides using high performance liquid chromotography with isoluminal chemiluminescence detection. Methods Enzymol. 186: 371-380.
35. Hassett, C., R. Richter, R. Humbert, C. Chapline, J. W. Crabb, C. J. Omiecinski, and C. E. Furlong. 1991. Characterization of cDNA clones encoding rabbit and human serum paraoxonase: the mature protein retains its signal sequence. Biochemistry. 30: 10141-10149.
36. Abbott, C. A., M. I. Mackness, S. Kumar, A. J. Boulton, and P. N. Durrington. 1995. Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. Arterioscler. Thromb. Vasc. Biol. 15: 1812-1818.
37. Ikeda, Y., T. Suehiro, M. Inoue, Y. Nakauchi, T. Morita, K. Arii, H. Ito, Y. Kumon, and K. Hashimoto. 1998. Serum paraoxonase activity and its relationship to diabetic complications in patients with non-insulin-dependent diabetes mellitus. Metabolism. 47: 598-602.
38. Mackness, M. I., D. Harty, D. Bhatnagar, P. H. Winocour, S. Arrol, M. Ishola, and P. N. Durrington. 1991. Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitus. Atherosclerosis. 86: 193-199.
39. McElveen, J., M. I. Mackness, C. M. Colley, T. Peard, S. Warner, and C. H. Walker. 1986. Distribution of paraoxon hydrolytic activity in the serum of patients after myocardial infarction. Clin. Chem. 32: 671-673.
40. Jennes, D. E., B. Lowin, M. C. Peitsch, A. Bottchert, G. Schmitz, and J. Tschopp. 1990. Clusterin (complement lysis inhibitor) forms a high density lipoprotein complex with apoliprotein A-I in human plasma. J. Biol. Chem. 266: 11030-11036.
41. Choi-Miura, N. H., S. T. Ohtaki, H. Nakamura, S. Isgizawa, Y. Takagi, K. Gomi, and M. Tomita. 1993. Elevated complement activities of sera from patients with high density lipoprotein deficiency (Tangier disease): the presence of normal level of clusterin and the possible implication in the atherosclerosis. Clin. Exp. Immunol. 93: 242-247.
42. Burkey, B. F., W. D. Stuart, and J. A. K. Harmony. 1992. Hepatic apolipoprotein J is secreted as a lipoprotein. J. Lipid Res. 33: 1517-1526.
43. Thrift, R., T. M. Forte, B. E. Cahoon, and V. G. Shore. 1986. Characterization of lipoproteins produced by the human liver cell line, Hep 2, under defined conditions. J. Lipid Res. 27: 236-250.
44. Rader, D. J., K. Ikewaki, N. Duverger, H. Schmidt, H. Pritchard, J. Frohlich, M. Clerc, M. F. Dumon, T. Fairwell, L. Zech, S. Santamarina-Fojo, and H. B. Brewer, Jr. 1994. Markedly accelerated catabolism of apolipoprotein A-II (apoA-II) and high density lipoproteins containing apoA-II in classic lecithin:cholesterol acyltransferase deficiency and fish-eye disease. J. Clin. Invest. 93: 321-330.